Project Grant HT94252410002
Award Date
2/1/24
Completion Date
1/31/27
Dollars Obligated
$962K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23284, USA
Similar Awards
The Defense Health Agency awarded a $1,204,746 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Old Dominion University Research Foundation (Odurf) for the project "Early Detection of Cancer Disparity and Treatment Resistance in TNBC". The grant, with a performance period from September 1, 2024 to January 31, 2027, will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the...
The federal Project Grant award of $1,788,135.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant aims to support advanced biomedical research to "TARGET GANGLIOSIDE GD2 TO OVERCOME CHEMOTHERAPY RESISTANCE IN TRIPLE-NEGATIVE BREAST CANCER" over the project period from Sep 1, 2025 to Aug 31, 2029. The award was granted to Virginia Commonwealth University, a public research university that has demonstrated...
This federal Project Grant award in the amount of $582,189.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at Virginia Commonwealth University (VCU) to investigate the role of histone H2A ubiquitination and the RSF1 gene in breast cancer. The 3-year award, starting on March 1, 2024, will fund personnel, facilities, and equipment to conduct basic, translational, and clinical research aimed at advancing...
The federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $807,400.00 to the Provincial Health Services Authority (BC Cancer) in Canada. The grant, awarded on May 1, 2024, supports a research project titled "DECODING HOW DISTINCT MECHANISMS OF GENOMIC INSTABILITY FOUND IN TNBC PATIENTS PROGRAM THE TISSUE MICROENVIRONMENT AND THERAPY RESPONSE AT METASTATIC SITES." This project aims to investigate...
The National Cancer Institute (NCI) awarded Virginia Commonwealth University (VCU) a $1,241,427 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a small molecule inhibitor called PDZ1I for treating advanced, metastatic triple negative breast cancer (TNBC). The project aims to formulate PDZ1I-nano for clinical use, characterize how it stimulates the immune system to suppress tumor growth, define the signaling pathways it targets, and combine it...
The Department of Defense's Defense Health Agency awarded Virginia Commonwealth University (VCU) a $568,461 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "READING HISTONE H2A UBIQUITINATION IN THE FUNCTION OF RSF1 IN BREAST CANCERS WITH RSF1 GENE AMPLIFICATION." The grant, effective from March 1, 2024 through February 28, 2027, will fund VCU's research to advance the scientific understanding of breast cancer and develop...
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive...
The Department of Defense's Defense Health Agency awarded a $1,836,611 Project Grant to Virginia Commonwealth University (VCU) under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2025, supports advanced biomedical research to develop a novel cell therapy for the treatment of advanced prostate cancer. VCU, a public research university in Richmond, Virginia, has demonstrated extensive capabilities in scientific research and technical...
The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027....